Valisanbe

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Valisanbe

Quick Facts

Property Description
Active Ingredient Diazepam
Form Tablets and Solution for Injection
Pharmacological Class Benzodiazepine Derivative
General Purpose To manage states of excessive neurological activity
Origin Synthetic Compound

What Type of Medicine is Valisanbe?

Valisanbe is a specific brand of a synthetic single-ingredient medicine; its core substance, Diazepam (INN), formally classifies it as a Benzodiazepine derivative. This classification places it within the larger category of Central Nervous System (CNS) depressants, a grouping clinically recognized for its ability to broadly diminish nerve activity. Diazepam's mechanism involves the facilitation of the inhibitory neurotransmitter, Gamma-Aminobutyric Acid (GABA), which is the body’s principal system for reducing neuronal excitability.

Valisanbe's Active Ingredient and Forms

The composition of Valisanbe is focused entirely on Diazepam, confirming it as a single active ingredient formulation. This synthetic compound is prepared in various high-level dosage forms, principally including Tablets for oral administration and a sterile Solution for injection intended for parenteral routes (intravenous or intramuscular use). The injectable preparation utilizes specialized excipients like propylene glycol, ethanol, and benzyl alcohol to ensure the stability and solubility of the Diazepam. The availability of both oral and injectable forms allows for use across different patient care settings, from outpatient management to acute hospital needs.

General Therapeutic Purpose and Role

The fundamental purpose of Valisanbe is to help relieve severe or acute symptoms associated with excessive neurological arousal. Due to its broad-spectrum CNS depressant activity, the medicine is utilized for its established roles as an Anxiolytic (to reduce anxiety and agitation), a powerful Sedative, a Skeletal muscle relaxant (to alleviate muscle spasm), and an effective Anticonvulsant. This comprehensive profile makes the medicine suitable for neutral use scenarios requiring immediate and reliable calming of central nervous system over-activity, such as managing acute tension or controlling sudden muscle hyperexcitability.

Regulatory References

  1. FDA Label (Diazepam Injection)

What side effects are possible with Valisanbe?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The safety profile for Valisanbe (Diazepam) is dominated by effects on the central nervous system (CNS) and psychiatric function, as documented in regulatory sources like the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Commonly Documented Effects The most frequently reported adverse effects reflect the drug’s general CNS depressant activity and include drowsiness (somnolence), fatigue, and ataxia (loss of muscle coordination/unsteadiness). Muscle weakness is also commonly reported, often categorized under Musculoskeletal disorders.

Serious Adverse Reactions and Constraints Official labeling emphasizes high-risk safety consequences, particularly the danger of profound sedation, respiratory depression, coma, and death when used concurrently with opioid medications or other CNS depressants. Abrupt discontinuation or rapid dose reduction can precipitate acute withdrawal reactions, including life-threatening seizures.

Psychiatric effects, classified under Psychiatric Disorders, include documented risks of dependence, abuse, and misuse. Paradoxical reactions, such as aggression, irritability, or hallucinations, have also been officially reported.

Population-Specific and Time-Related Safety

Safety information specifies constraints for certain patient groups. Older adults are more susceptible to dose-related CNS effects (e.g., severe confusion, unsteadiness). The medicine is contraindicated in severe hepatic insufficiency due to the risk of hepatic encephalopathy and in conditions like myasthenia gravis and severe respiratory insufficiency.

The risk of dependence is documented to increase with the dose and duration of therapy. Anterograde amnesia is another documented time-related pattern, occurring most often several hours following administration.

This structured regulatory profile defines the inherent safety boundaries for the medicine's use, highlighting specific risks and necessary physiological constraints.

Overdose and Emergency Response

Documented Overdose Manifestations

Official regulatory documents describe Valisanbe (Diazepam) overdose primarily through a continuum of Central Nervous System (CNS) depression. Overdose manifestations typically include drowsiness, mental confusion, and impaired motor function, such as ataxia (uncoordinated movement) and slurred speech. Other clinical signs documented in overdose cases are nystagmus (rapid eye movement), diminished reflexes, and hypotension (low blood pressure).


Severe Outcomes and Mandated Emergency Intervention

Severe toxicity is defined by the progression to profound sedation, coma, and life-threatening respiratory depression (slowed or stopped breathing). The risk of these severe outcomes, including death, is significantly increased by the concomitant use of other CNS depressants, particularly opioids and alcohol. Immediate medical attention must be sought for any suspected overdose.

Urgent medical care is specifically required if symptoms involve difficulty breathing or progression toward unresponsiveness. Management is largely symptomatic and supportive, including monitoring of vital signs and, where clinically appropriate, the cautious use of the benzodiazepine antagonist Flumazenil. The use of this reversal agent requires caution due to the documented risk of precipitating acute withdrawal reactions or seizures.

Therapeutic Uses of Valisanbe

What Valisanbe Treats: Main Uses and Benefits

The therapeutic role of Valisanbe (Diazepam) is to provide symptomatic support across conditions involving heightened physiological and neurological activity. In clinical practice, the medication is utilized to address acute and disruptive symptom patterns across several key domains.

Valisanbe is applicable within clinical settings that involve acute or disruptive symptom patterns, including the short-term relief of severe anxiety, management of muscle spasm and spasticity, control of acute convulsive episodes (like status epilepticus), and providing support during acute alcohol withdrawal syndrome. The medication may assist with maintaining functional stability by being used for managing symptoms that interfere with daily functioning.

“The medicine is used to manage symptom intensity when emotional or motor hyperexcitability becomes difficult to tolerate.”


Quick Fact: Relief for Neurological Overactivity The medicine is commonly used when short-term symptomatic assistance is needed to stabilize patients experiencing symptoms related to increased neurological or muscular activity, such as seizure clusters or severe tremors.

This approach contributes to easing the overall symptom load and supports improved comfort during periods of heightened symptoms.

Eligibility and Restrictions for Use

Who Can and Cannot Use Valisanbe?

Absolute Contraindications

Valisanbe (Diazepam) is explicitly prohibited by regulatory authorities for use in patients with certain severe pre-existing conditions. These contraindications include Myasthenia Gravis, Severe Hepatic Insufficiency or failure, Severe Respiratory Insufficiency, Sleep Apnea Syndrome, and Acute Narrow-Angle Glaucoma. Use is also strictly disallowed for individuals with a known Hypersensitivity to diazepam or any of its excipients.

Age-Group and Organ Function Restrictions

The medicine is strictly contraindicated in pediatric patients under 6 months of age because safety and effectiveness are not established for this group. Older adults are eligible but are a restricted population that requires special care. Patients with mild or moderate hepatic impairment or impaired renal function must use the medicine with extreme caution, as official labeling indicates a risk of drug or metabolite accumulation.

Special Populations and Comorbidity Rules

Use is not recommended as monotherapy for psychotic illness or for anxiety associated with latent depression. For Pregnancy, the medicine is generally not recommended, and the patient must be apprised of the potential hazard to the fetus. Breastfeeding is not recommended because the drug is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Valisanbe (Diazepam) based on two primary risks: pharmacodynamic enhancement and pharmacokinetic modulation.

Classification Property Official Regulatory Statement
Interaction severity classification Major / Highly Clinically Significant: Combinations with Opioid Analgesics and Alcohol carry the highest risk, documented with an FDA Boxed Warning for profound sedation, respiratory depression, coma, and death.
Mechanistic basis (in regulatory sources) Pharmacokinetic: Inhibition or induction of the hepatic enzymes mathbfCYP2C19 and mathbfCYP3A4. Pharmacodynamic: Additive Central Nervous System (CNS) depressant effects.

The co-administration of Valisanbe with other CNS depressants, including opioids, barbiturates, and certain antipsychotic or anticonvulsant agents, is officially restricted due to the combined sedative effects. Substances that inhibit mathbfCYP2C19 or mathbfCYP3A4 (e.g., certain antibiotics and antidepressants like Fluoxetine and Omeprazole) are documented to decrease the rate of elimination, potentially increasing Valisanbe's systemic concentration.

Simultaneous ingestion of Alcohol (Ethanol) is officially not recommended due to significantly enhanced depressant risks. Oral administration with food is documented to delay absorption and decrease peak plasma concentration (mathbfCmax) by approximately 27%. The interaction profile is further constrained by population-specific notes that acknowledge decreased clearance in the elderly and those with impaired hepatic function, amplifying documented adverse risks.

Mechanism of Action

Valisanbe exerts its effects through a unique dual mechanism, acting on distinct ion channels in both the Central Nervous System ( CNS) and peripheral sensory neurons. This combination leads to concurrent modulation of neuronal excitability through the central and peripheral pathways.

Valisanbe acts as a Positive Allosteric Modulator ( PAM) at the GABAA receptor, particularly targeting the alpha2 and alpha3 subunits. This action increases the activity of endogenous GABA, promoting the influx of chloride ions that hyperpolarizes central neurons. The resulting cascade leads to decreased probability of central neuronal action potentials through increased chloride conductance.

The drug also functions as an open-channel blocker of Voltage-Gated Sodium Channels ( VGSCs), including Na v1.7 and Na v1.8, located on peripheral sensory nerve fibers. By physically obstructing the channel pore, Valisanbe prevents the necessary influx of sodium ions required for an action potential, effectively disrupting the conduction of electrical signals along these fibers.

Dosage and Administration Information

How Valisanbe is Used: Official Administration Guidelines

The usage of Valisanbe (Diazepam) involves specific parameters regarding its route, dose, frequency, and administration technique. These guidelines ensure the medicine is applied correctly for both acute and maintenance use.

Administration Routes and Standard Dosing

The medication is available for several approved administration methods, which align with the need for immediate or sustained action.

Parameter Official Instruction
Route of Administration Oral (tablets), Intravenous (IV), Intramuscular (IM), Rectal (gel/solution), and Intranasal (spray).
Standard Dose Range Oral maintenance doses typically range from 2 mg to 10 mg for most indications. Acute intravenous doses are typically 5 mg to 10 mg, which may be repeated after a specific interval.
Frequency Pattern Oral use for ongoing conditions is generally administered in divided doses (e.g., three to four times daily). For acute episodes, dosing is administered as needed, according to strict time limits and maximum cumulative amounts.
Course Duration Use is advised to be short-term, typically no longer than 8 to 12 weeks total, including the necessary period of dose reduction.

Procedural and Population-Specific Instructions

Established clinical protocols define procedural constraints to ensure proper delivery of the medication:

  • IV Administration: The solution must be administered slowly, at a controlled rate not exceeding 5 mg per minute. The solution must not be diluted or mixed with other products in the same syringe.
  • Oral Intake: Tablets may be taken with or without food.
  • Dose Adjustment: Initial dosing involves a reduction for older adults and individuals with hepatic impairment, with gradual adjustment based on clinical need.

These administration rules establish a clear protocol for using the medicine across different clinical scenarios and patient populations.

Recent Clinical Evidence

Research evidence / Overview of studies for Valisanbe

Evidence for Acute Convulsive Episodes and Seizure Clusters

This section will summarize the structure of the clinical trials, including placebo-controlled and active-comparator studies, that explored the compound's use in the immediate management of acute seizure activity. It will describe the time-based endpoints and patient groups evaluated by these key studies.

The research base consists of large-scale Randomized Controlled Trials (RCTs) applied in research contexts involving fluctuating or unstable symptoms, such as seizure clusters. These studies often compared the compound to a placebo or to other established medicines. Researchers examined outcomes describing episodic or acute changes, such as the specific time elapsed until convulsive activity ceased, and the proportion of people who did not experience another seizure during a defined observation period.

Findings describe patterns observed in these studies, where the compound's use was monitored across defined time intervals. Studies focused on acute measurements and tracked the potential for seizures to recur. Systematic reviews and regulatory assessments described the evidence landscape for this compound's use in the immediate management of acute convulsive episodes.

What remains uncertain involves the optimal approach for characterizing the compound’s disposition in the body. While research describes how the compound was observed in various populations, data for certain groups remain insufficient, particularly regarding the specific dosing for the youngest pediatric subgroups.

Evidence for Short-Term Anxiety and Acute Agitation

This area will outline the research base consisting of Randomized Controlled Trials (RCTs) and systematic reviews, describing how researchers measured the evolution of anxiety and agitation symptoms. It will specify the typical duration of these studies and the adult populations examined.

Valisanbe was studied for conditions involving periods of heightened symptoms, such as severe anxiety and acute agitation. Studies explored how symptoms evolved in the observed populations through the use of double-blind Randomized Controlled Trials (RCTs) and systematic reviews. The populations studied included adults with diagnoses consistent with anxiety disorders. These trials focused on outcomes capturing phases of heightened symptom activity, using standardized scales to measure symptom intensity.

Studies reported measurements of values recorded on clinical anxiety scale scores across the short-term duration of the trials. Findings describe patterns observed in the studies related to symptomatic evolution. Systematic reviews described the outcomes of trials that primarily focused on how symptoms evolved over acute periods.

Evidence is limited regarding outcomes over extended periods, as the follow-up durations were typically short-term, often limited to approximately four weeks. Certainty remains low regarding the generalizability of some findings, as evidence quality varies across studies and sometimes used different criteria for defining the patient populations.

Evidence for Acute Alcohol Withdrawal and Detoxification

This part will detail the types of comparative trials and reviews that focused on symptomatic management during the acute phase of alcohol withdrawal. The summary will include the standardized scales used by researchers to assess changes in tremor, agitation, and the prevention of severe complications.

Valisanbe was evaluated in research exploring temporary physiological imbalance and conditions associated with acute or disruptive episodes, specifically during alcohol withdrawal. Systematic reviews and comparative Randomized Controlled Trials (RCTs) against other medicines were used to explore short-term symptom changes. Studies monitored outcomes related to physiological strain or stress in the observed populations, using standardized assessment scales to measure symptom intensity or variability. Outcomes monitored also included the occurrence of acute complications.

Data show patterns related to the evolution of symptoms observed during the acute phase of treatment. Research describes how symptoms evolved in the observed populations, and the evidence contributes to understanding symptom patterns in the acute withdrawal setting. Studies report that symptom patterns were monitored, often over a defined time interval of approximately two days.

Minimal trial data are available to compare different approaches to treatment administration in the most severe stages of withdrawal. Comparative evidence is lacking for how various methods of dosing may influence outcomes in high-burden settings. Furthermore, research does not determine whether an individual will respond similarly to group patterns, as findings describe group patterns, not personal outcomes.

Evidence for Skeletal Muscle Spasm and Spasticity

This heading will cover the adjunctive therapy trials and observational studies that investigated the compound's effect on muscle tone and symptom severity. It will describe the various follow-up durations used to assess relief in patients with muscle spasms from injury or spasticity from neurological conditions.

Research examined Valisanbe in adjunctive therapy trials for conditions marked by functional limitations due to muscle spasticity or spasm. Research explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, using tools to measure muscle tone and severity of spasm. The study populations included adults with acute spasm and both adults and children with chronic spasticity from central nervous system disorders.

Findings describe patterns observed in the studies where measures of muscle tone evolved in the observed populations, and contributes to the broader evidence landscape for the compound's use as an adjunctive agent. Studies monitored changes in physical discomfort over follow-up durations that ranged from short-term (days) to intermediate periods (months) for some chronic conditions.

Evidence quality varies across studies, and data for certain groups remain insufficient. The available research primarily characterizes the compound as an agent used alongside other treatments, and comparative evidence is lacking regarding its use as a long-term, standalone treatment for spasticity.

Research in Special Populations and Age Groups

This section will outline what is known about the research conducted in specific patient groups, including studies that have evaluated the use of Valisanbe in children (pediatric patients) and older adults.

Research examined Valisanbe in studies focusing on pediatric patients (children and infants aged ge 3 months) requiring acute intervention for convulsive episodes. Research describes how the compound was observed in this population and reports outcomes measured during the study period. Specialized studies also explored the compound's use in older adults (aged ge 65 years) within the context of anxiety management, with researchers examining patient-reported experiences.

The results apply only to the populations studied, and long-term effects are not fully established for some of these groups. Specific research provides context but not individual predictions, and data for certain subgroups within these populations remain insufficient.

Long-Term Outcomes and Research Gaps

This final section will summarize the extent of the available data regarding outcomes over extended periods, particularly the durability of response and the general lack of long-term evidence. It will synthesize the main limitations and areas where official sources have noted that more research is needed.

Research provides insight into short-term changes across all indications, but there is limited information for long-term outcomes. The follow-up durations were typically limited to the acute or short-term phases of treatment. For conditions like severe anxiety and alcohol withdrawal, the focus of the evidence is on short-term symptom patterns, with certainty remaining low about the effects beyond that period.

Research highlights what is known and what is still uncertain; overall, the data show patterns related to rapid, short-term changes in symptoms. Areas where more research is needed include optimal dosing for certain populations and further comparative evidence against alternative agents for certain non-acute indications.

Key Studies & References

  1. Diazepam - StatPearls (Source covering multiple indications and pharmacology)

Frequently Asked Questions (FAQ)

Common questions about Valisanbe (FAQ)

Q: How does Valisanbe differ from similar common treatments?

Valisanbe is classified as a benzodiazepine, a medication that acts as a central nervous system (CNS) depressant. Official product information describes the medicine as a long-acting compound. This means its active substance and its breakdown product stay present in the body for an extended period compared to some shorter-acting agents in the same class.

Q: Is Valisanbe taken daily?

According to official administration guidelines, use for ongoing or chronic conditions, such as anxiety and muscle spasm, is generally described as being administered in divided doses. This pattern suggests that daily administration is typical for maintenance use, often taken multiple times throughout the day.

Q: Can Valisanbe cause fatigue or tiredness?

Yes, regulatory documents list effects such as drowsiness (somnolence) and general fatigue as commonly documented adverse effects of this medicine. These effects reflect the drug's overall depressant action on the central nervous system.

Q: Does Valisanbe affect sleep patterns?

Official pharmacological data indicates that this medicine can affect the architecture of sleep. This includes the documented suppression of specific stages of sleep, such as REM sleep and slow wave sleep.

Q: Is it true that Valisanbe can cause liver issues?

The official product information lists severe hepatic insufficiency (severe liver failure) as a condition where the medicine is explicitly prohibited for use. The restriction is related to the liver's decreased ability to process and eliminate the drug, which can lead to its accumulation and increased potential for adverse risks.

Q: Does Valisanbe interact with birth control pills?

Official interaction information notes that oral contraceptives may inhibit the enzymes responsible for breaking down this medicine. This effect can decrease the rate at which the drug is eliminated from the body, potentially increasing its concentration and the risk of prolonged sedative effects.

Q: Are there any foods or supplements that should be avoided with Valisanbe?

Regulatory documents state that alcohol consumption is officially restricted (or not recommended) due to the high risk of severe sedation. Additionally, grapefruit and grapefruit juice may interact with the medicine's metabolism. It is also noted that some herbal supplements, especially those used for anxiety or sleep, may increase the drowsy effects of the medicine.

Q: Are the research findings on Valisanbe publicly available?

Yes, information derived from clinical trials and research that supports the official approved uses of the medicine is made publicly available through regulatory agency documents, such as FDA Prescribing Information and NIH literature.

Q: What happens if I suddenly stop taking Valisanbe?

Regulatory warnings describe that cessation of the medicine can be associated with acute withdrawal reactions. These reactions may include common symptoms such as headaches, muscle pain, and restlessness, and in serious situations, they can lead to life-threatening seizures.

Q: Does Valisanbe have a known effect on mood or anxiety?

Valisanbe is officially utilized for its anxiolytic effect, meaning it is used to help relieve symptoms of anxiety. However, regulatory documents also list that paradoxical reactions may occur, including unexpected changes in mental health such as agitation, restlessness, or new or worsening anxiety or depression.

Q: How long does it typically take to see a noticeable effect from Valisanbe?

Official pharmacological data describes a relatively rapid onset of action. When the medicine is taken by mouth, effects typically begin within 15 to 60 minutes. For forms administered intravenously, the documented effects are typically observed within one to three minutes.

Q: If I miss a dose of Valisanbe, what should I generally expect?

The official documentation describes that for a missed dose, the regulatory instructions advise that the dose should be skipped if it is almost time for the next scheduled dose, with the user returning to the regular schedule without taking a double dose.

Q: Is Valisanbe safe to use if I have high blood pressure?

High blood pressure is not listed as an absolute prohibition for use in the official contraindications. The medicine is not intended to treat blood pressure; however, regulatory information notes that it can cause a drop in blood pressure as a secondary effect.

Q: Is Valisanbe often prescribed for use in children?

Official documents include specific dosing recommendations for the oral form of the medicine for children starting at six months of age. Dosing recommendations are also provided for certain acute seizure products in children two years of age and older. However, use is strictly prohibited for infants under six months of age.

Q: Are there different forms or strengths of Valisanbe available?

Yes, according to official documents, the medicine is available in multiple forms to suit different needs. These forms include oral tablets (such as 2 mg and 5 mg strengths), as well as liquid oral solutions and specialized preparations for rectal or intranasal administration.

Q: What is the difference between Valisanbe and its generic equivalent?

Official regulatory sources confirm that the brand name Valisanbe and its generic equivalent contain the identical active pharmaceutical ingredient and are documented to work in the same manner. Any differences are typically related to non-medical factors such as the product name, cost, or the specific color and shape of the pill.

Q: How quickly does Valisanbe leave the body?

This is described by the drug's elimination half-life, which is the time it takes for half of the drug to be cleared. Official pharmacokinetic data indicates that the half-life of the parent compound can be up to 48 hours, while its active breakdown product can remain in the body for an even longer duration, potentially up to 120 hours.

Q: Can Valisanbe be taken with antacids?

Antacids are generally categorized as having a minor potential for interaction with this medicine. However, official documents specifically list that other, stronger acid-reducing medications, such as cimetidine and omeprazole, are considered to have a recognized interaction potential.

Q: Does Valisanbe cause weight gain or weight loss?

Official regulatory sources generally indicate that this medicine does not typically cause changes in body weight as a side effect. While changes to appetite have been reported, they are not listed among the commonly documented adverse effects.

Q: What kind of monitoring is typically required when taking Valisanbe?

Regulatory guidelines often specify that monitoring is necessary to track potential changes in mental health, such as agitation or depression, and for observing side effects. This monitoring is also essential for determining if a dose adjustment is necessary, particularly in patients with impaired liver function.

Q: Is Valisanbe considered a relatively new or older drug?

The core active substance of this medicine is considered an older drug in the pharmaceutical landscape. It was first patented and subsequently marketed in the United States in 1963.

Q: What should I do if I have an allergic reaction to Valisanbe?

Official documentation specifies that signs of an allergic reaction (such as difficulty breathing, swelling of the face/throat, or rash) warrant immediate emergency medical attention.

Q: What kind of health care professional usually prescribes Valisanbe?

As the active substance is classified as a controlled substance, the medicine requires a prescription. It is prescribed by a qualified healthcare professional, such as a doctor or physician, who is licensed to dispense such medications.

Q: Can Valisanbe be taken with common vitamins or mineral supplements?

Official guidance emphasizes the importance of informing a healthcare professional about all vitamins, minerals, and nutritional supplements being taken. This is because there is not enough specific safety information available to determine the interaction potential for every possible combination.

Q: Why are certain patients advised not to use Valisanbe?

Official contraindications are based on the risk of exacerbating severe pre-existing conditions. For example, the medicine is not used in severe respiratory problems because its depressant effect on the central nervous system could worsen breathing. It is also prohibited in severe liver impairment because the drug would not be properly cleared from the body.

Q: Do effectiveness results from clinical trials on Valisanbe last over time?

Official summaries of the research evidence focus primarily on short-term outcomes, such as symptom changes during acute treatment phases. Regulatory sources note that information regarding the durability of the response and the effects over extended, long-term periods is limited.

Q: Does Valisanbe contain gluten, lactose, or other common allergens?

Official excipient documentation shows that certain tablet forms of the medicine are made with ingredients like lactose. Liquid oral suspensions may also contain substances like sucrose and other specialized excipients.

Q: What is the physical appearance of the Valisanbe pill or form?

The physical appearance varies depending on the strength and the form of the medicine. For instance, official descriptions state that some 2 mg tablets are round and white, while 5 mg tablets may be described as round and yellow, typically with identifying markings.

Q: Can Valisanbe affect fertility in men or women?

Official sources state that there is no clear human evidence to suggest that this medicine reduces fertility in men or women. However, some preclinical studies in animals have noted specific hormonal changes, such as a decrease in the release of prolactin.

How should Valisanbe be stored and disposed of?

The management and disposal of Valisanbe (Diazepam) are subject to official regulatory requirements to ensure product stability and prevent misuse.

Storage Component Official Requirement
Temperature Tablets: Store below 30 C (86°F). Injection: Store at Controlled Room Temperature (20 C to 25 C)
Environmental Protection Protect from light and store in a cool, dry place away from moisture and direct heat.
Container Restriction Avoid intravenous administration using PVC (polyvinyl chloride) bags or sets due to the risk of drug adsorption.
In-Use Stability The injectable solution is for single-use only; discard any unused residue immediately.

All Valisanbe preparations must be stored out of the sight and reach of children and kept in a secure location due to the product's status as a controlled substance. Unused or expired medication must be disposed of according to local regulations as advised by healthcare authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Valisanbe found in:

A-Z Index: